A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
NCT01132690
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
11
Enrollment
INDUSTRY
Sponsor class
Conditions
Gaucher Disease
Interventions
DRUG:
Taliglucerase alfa
Sponsor
Pfizer